ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: Implications for electrical remodeling

Heart Rhythm

Volumn 6, Issue 9, 2009, Pages 1327-1332

  Watanabe, Hiroshi ^a,c   Kaiser, Daniel W ^a   Makino, Seiko ^b   MacRae, Calum A ^b   Ellinor, Patrick T ^b   Wasserman, Brian S ^a   Kannankeril, Prince J ^a   Donahue, Brian S ^a   Roden, Dan M ^a   Darbar, Dawood ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NIIGATA UNIVERSITY   (Japan)

Author keywords

Angiotensin converting enzyme; Arrhythmia; Atrial fibrillation; Electrocardiogram; Genetics; Heart block

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; ANGIOTENSIN II;

ADULT; AGED; ALLELE; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR PARAMETERS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; ELECTROCARDIOGRAM; ENZYME ACTIVITY; FEMALE; GENE ACTIVITY; GENETIC ASSOCIATION; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART BLOCK; HEART DISEASE; HEART ELECTROPHYSIOLOGY; HUMAN; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; P WAVE; PR INTERVAL; PRIORITY JOURNAL; SINUS RHYTHM; ATRIAL FIBRILLATION; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETICS; HEART ATRIOVENTRICULAR NODE; HEART ATRIUM; HEART DISEASES; HEART VENTRICLE REMODELING; INNERVATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PATHOPHYSIOLOGY; STATISTICAL MODEL;

ADULT; ANGIOTENSIN II; ATRIAL FIBRILLATION; ATRIOVENTRICULAR NODE; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HEART ATRIA; HEART BLOCK; HEART DISEASES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; VENTRICULAR REMODELING;

EID: 68949220065     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2009.05.014     Document Type: Article

References (36)

1. Cambien F., Poirier O., Lecerf L., et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359 (1992) 641-644
2. Raynolds M.V., Bristow M.R., Bush E.W., et al. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 342 (1993) 1073-1075
3. Schunkert H., Hense H.W., Holmer S.R., et al. Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 330 (1994) 1634-1638
4. Marian A.J., Yu Q.T., Workman R., et al. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet 342 (1993) 1085-1086
5. Gensini F., Padeletti L., Fatini C., et al. Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. Pacing Clin Electrophysiol 26 1 Pt 2 (2003) 295-298
6. Tsai C.T., Hwang J.J., Chiang F.T., et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation: a regression approach for the detection of gene-gene interactions in a large hospitalized population. Cardiology 111 (2008) 1-7
7. O'Donnell C.J., Lindpaintner K., Larson M.G., et al. Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 97 (1998) 1766-1772
8. Rigat B., Hubert C., Alhenc-Gelas F., et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86 (1990) 1343-1346
9. Danser A.H., Schalekamp M.A., Bax W.A., et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. Circulation 92 (1995) 1387-1388
10. Boldt A., Scholl A., Garbade J., et al. ACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol 101 (2006) 261-267
11. Yu H., Gao J., Wang H., et al. Effects of the renin-angiotensin system on the current I(to) in epicardial and endocardial ventricular myocytes from the canine heart. Circ Res 86 (2000) 1062-1068
12. Zhang T.T., Takimoto K., Stewart A.F., et al. Independent regulation of cardiac Kv4.3 potassium channel expression by angiotensin II and phenylephrine. Circ Res 88 (2001) 476-482
13. + current via the AT1 receptor in guinea pig atrial myocytes. Circulation 113 (2006) 1278-1286
14. Fischer R., Dechend R., Gapelyuk A., et al. Angiotensin II-induced sudden arrhythmic death and electrical remodeling. Am J Physiol Heart Circ Physiol 293 (2007) H1242-H1253
15. Darbar D., Motsinger A.A., Ritchie M.D., et al. Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. Heart Rhythm 4 (2007) 743-749
16. Darbar D., Kucera G., Stubblefield T., et al. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation 117 (2008) 1927-1935
17. Ellinor P.T., Nam E.G., Shea M.A., et al. Cardiac sodium channel mutation in atrial fibrillation. Heart Rhythm 5 (2008) 99-105
18. Pretorius M., Donahue B.S., Yu C., et al. Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass. Circulation 116 11 Suppl (2007) I1-I7
19. Warsy I., Norris K., Roden D., et al. Ibutilide-induced QT prolongation varies markedly among individuals in a gender and exercise-independent fashion. Circulation 110 (2004) 623
20. Choy A.M., Darbar D., Dell'Orto S., et al. Exaggerated QT prolongation after cardioversion of atrial fibrillation. J Am Coll Cardiol 34 (1999) 396-401
21. Priori S.G., and Napolitano C. Role of genetic analyses in cardiology: part I: mendelian diseases: cardiac channelopathies. Circulation 113 (2006) 1130-1135
22. Darbar D. Genetics of atrial fibrillation: rare mutations, common polymorphisms, and clinical relevance. Heart Rhythm 5 (2008) 483-486
23. Knollmann B.C., and Roden D.M. A genetic framework for improving arrhythmia therapy. Nature 451 (2008) 929-936
24. Sotoodehnia N., Siscovick D.S., Vatta M., et al. Beta2-adrenergic receptor genetic variants and risk of sudden cardiac death. Circulation 113 (2006) 1842-1848
25. Arking D.E., Pfeufer A., Post W., et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet 38 (2006) 644-651
26. Newton-Cheh C., Guo C.Y., Larson M.G., et al. Common genetic variation in KCNH2 is associated with QT interval duration: the Framingham Heart Study. Circulation 116 (2007) 1128-1136
27. Fitzgerald P.T., and Ackerman M.J. Drug-induced torsades de pointes: the evolving role of pharmacogenetics. Heart Rhythm 2 2 Suppl (2005) S30-S37
28. Xiao H.D., Fuchs S., Campbell D.J., et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol 165 (2004) 1019-1032
29. Kasi V.S., Xiao H.D., Shang L.L., et al. Cardiac restricted angiotensin converting enzyme overexpression causes conduction defects and connexin dysregulation. Am J Physiol Heart Circ Physiol 2 (2007) 2
30. Goette A., Staack T., Rocken C., et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 35 (2000) 1669-1677
31. Kumagai K., Nakashima H., Urata H., et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 41 (2003) 2197-2204
32. Lenz O., Schmid B., Kilter H., et al. Effects of angiotensin II and angiotensin-converting enzyme inhibitors on human myocardium. Eur J Pharmacol 294 (1995) 17-27
33. Frustaci A., Chimenti C., Bellocci F., et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96 (1997) 1180-1184
34. Birnie D.H., Gollob M., and Healey J.S. Clinical trials, the renin angiotensin system and atrial fibrillation. Curr Opin Cardiol 21 (2006) 368-375
35. Healey J.S., Baranchuk A., Crystal E., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45 (2005) 1832-1839
36. Smith Jr. S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113 (2006) 2363-2372